WHO ICTRP trial
Randomized phase II study with Carboplatin in combination with Decitabine versus…
EUCTR2017-004099-71-IT · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2017-004099-71-IT |
|---|---|
| Public title | Randomized phase II study with Carboplatin in combination with Decitabine versus standard chemotherapy at physician’s choice |
| Scientific title | Randomized Phase II study on Decitabine plus Carboplatin versus physician’s choice chemotherapy in recurrent, platinum-resistant ovarian cancer - MITO 29 |
| Primary sponsor | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Italy |
| Conditions | Platinum-resistant ovarian cancer MedDRA version: 20.0 Level: LLT Classification code 10006888 Term: Ca ovary System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: PACLITAXEL MYLAN GENERICS - 6 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML Product Name: Paclitaxel Product Code: [Paclitaxel] Pharmaceutical Form: Solution for infusion INN or Proposed INN… |
| Registration date | Apr 11, 2020 |
| Target size | 119 |
| Secondary IDs | MITO29;ISRCTN00000000;NCT00000000;MITO 29 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: